Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in Barcelona this weekend as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Max Gelman

Senior Editor

Sign up to read this article for free.

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Nu­va­tion Bio to head to FDA with pooled ROS1-pos­i­tive lung can­cer da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks